Breaking News Instant updates and real-time market news.

MMS

Maximus

$60.51

-0.3901 (-0.64%)

, PAYC

Paycom

$70.06

0.16 (0.23%)

11:05
08/09/17
08/09
11:05
08/09/17
11:05

Canaccord Genuity to hold a conference

37th Annual Growth Conference is being held in Boston on August 9-10 with companies webcasting presentations; not all presentations will be webcasted. Webcast Link

MMS

Maximus

$60.51

-0.3901 (-0.64%)

PAYC

Paycom

$70.06

0.16 (0.23%)

TTOO

T2 Biosystems

$2.96

-0.14 (-4.52%)

ZFGN

Zafgen

$3.41

-0.08 (-2.29%)

QDEL

Quidel

$32.24

-0.01 (-0.03%)

PI

Impinj

$37.42

0.38 (1.03%)

MULE

MuleSoft

$21.41

-0.12 (-0.56%)

SELB

Selecta Biosciences

$17.89

-0.09 (-0.50%)

MDXG

MiMedx

$15.64

0.41 (2.69%)

SHOO

Steven Madden

$42.50

0.1 (0.24%)

BNFT

Benefitfocus

$29.05

1.075 (3.84%)

EW

Edwards Lifesciences

$116.14

-0.02 (-0.02%)

FH

FORM Holdings Corp

$1.13

-0.01 (-0.88%)

ITI

Iteris

$6.40

-0.17 (-2.59%)

NVRO

Nevro

$85.50

-1.13 (-1.30%)

PEN

Penumbra

$86.50

2.4 (2.85%)

KITE

Kite Pharma

$120.13

6.58 (5.79%)

ELGX

Endologix

$4.31

0.15 (3.61%)

ZEN

Zendesk

$25.81

-0.13 (-0.50%)

LCI

Lannett

$17.28

0.675 (4.07%)

UPLD

Upland Software

$23.60

-0.25 (-1.05%)

  • 09

    Aug

  • 09

    Aug

  • 10

    Aug

  • 10

    Aug

  • 11

    Aug

  • 14

    Aug

  • 15

    Aug

  • 16

    Aug

  • 16

    Aug

  • 21

    Aug

  • 28

    Aug

  • 05

    Sep

  • 14

    Sep

  • 28

    Sep

  • 13

    Nov

  • 14

    Nov

  • 29

    Nov

MMS Maximus
$60.51

-0.3901 (-0.64%)

05/04/17
MAXM
05/04/17
DOWNGRADE
MAXM
Hold
Maximus downgraded to Hold on valuation at Maxim
Maxim analyst Brian Kinstlinger downgraded Maximus to Hold from Buy citing valuation following the company's Q2 results. The analyst keeps a $66 price target for the shares. Maximus looks fully valued, especially given the pause in government awards for health and human services, Kinstlinger tells investors in a post-earnings research note.
05/25/17
KEYB
05/25/17
DOWNGRADE
KEYB
Sector Weight
Maximus downgraded to Sector Weight from Overweight at KeyBanc
KeyBanc analyst Jason Gurda downgraded Maximus to Sector Weight citing valuation and the current "pause" in federal procurement activity that could be longer and deeper than expected.
05/25/17
05/25/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. PayPal (PYPL) downgraded to Hold on valuation at Stifel with analyst Scott Devitt saying shares have reached his price target of $51 but said the company remains well positioned for long-term growth. 2. Etsy (ETSY) downgraded to Neutral from Buy at Citi with analyst Mark Kelley saying that while the stock has run on the company's review of alternatives, a takeover is not imminent. The stock could be worth $21-$22 if Etsy is acquired, but $7 if the company remains a stand-alone with little to no improvement in operational performance, Kelley tells investors in a research note. He tells investors to hold the stock if already involved and raised his price target for the shares to $14 from $13. 3. Fang Holdings (SFUN) downgraded to Neutral from Buy at UBS with the firm citing valuation and saying the eCommerce services and primary housing advertising still faces market risks and execution uncertainty. 4. Maximus (MMS) downgraded to Sector Weight from Overweight at KeyBanc with analyst Jason Gurda citing valuation and the current "pause" in federal procurement activity that could be longer and deeper than expected. 5. Hortonworks (HDP) downgraded to Neutral from Buy at Mizuho with analyst Abby Lamba citing the recent strength in shares and raised its price target to $14. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/05/17
JEFF
05/05/17
DOWNGRADE
Target $63
JEFF
Hold
Maximus downgraded to Hold from Buy at Jefferies
Jefferies analyst David Styblo downgraded Maximus to Hold citing valuation, a lack of catalysts and a slowing pipeline. The analyst believes investors are being too optimistic about a reacceleration in revenue. He lowered his price target for the shares to $63 from $64.
PAYC Paycom
$70.06

0.16 (0.23%)

08/02/17
OPCO
08/02/17
NO CHANGE
Target $75
OPCO
Outperform
Paycom price target raised to $75 from $65 at Oppenheimer
Oppenheimer analyst Brian Schwartz raised his price target for Paycom to $75 from $65 after the company reported "very solid" Q2 results against the toughest quarterly comparison this fiscal year. He reiterates an Outperform rating on the shares.
08/02/17
KEYB
08/02/17
NO CHANGE
Target $94
KEYB
Sector Weight
Paycom price target raised to $94 from $73 at KeyBanc
KeyBanc analyst Brent Bracelin raised his price target for Paycom Software to $94 saying the company reported "another solid quarter of execution." The analyst now has increased confidence that the company can sustain 25%-35% revenue growth while maintaining 20%-plus EBITDA margin. Political risk around Affordable Care Act repeal or reform "has proven to be more bark than bite for Paycom this year so far," Bracelin writes in a research note. He has a Sector Weight rating on the shares.
08/02/17
WELS
08/02/17
NO CHANGE
WELS
Paycom reported 'strong' Q2 results, says Wells Fargo
Wells Fargo says that Paycom reported "strong" Q2 results and provided "conservative" guidance. The firm thinks that the company is well-positioned to gain market share and reiterates an Outperform rating.
08/02/17
KEYB
08/02/17
NO CHANGE
KEYB
Paycom 'bull case outlook' raised to $94 from $73 at KeyBanc
KeyBanc analyst Brent Bracelin believes that Paycom's better than expected results were driven by "solid execution" and share gains. The analyst says the results "validate Paycom's differentiated approach in cloud payroll and HR software for small and mid-size businesses." The analyst raised his bull case outlook on the stock to $94 from $73 but keeps a Sector Weight rating.
TTOO T2 Biosystems
$2.96

-0.14 (-4.52%)

03/14/17
MSCO
03/14/17
DOWNGRADE
Target $5
MSCO
Underweight
T2 Biosystems downgraded to Underweight from Equal Weight at Morgan Stanley
Morgan Stanley analyst Steve Beuchaw downgraded T2 Biosystems to Underweight and lowered his price target for the shares to $5 from $6. The company last week disclosed that its CFO Shawn Lynch resigned effective immediately. Lynch indicated that he resigned for personal reasons and that his resignation was not the result of any disagreement with the management or the board, T2 added. The stock closed the trading day unchanged at $6.07.
11/10/16
LEER
11/10/16
INITIATION
Target $5
LEER
Market Perform
T2 Biosystems resumed with a Market Perform at Leerink
Leerink analyst Puneet Souda resumed coverage of T2 Biosystems with a Market Perform rating and $5 price target.
05/08/17
BTIG
05/08/17
UPGRADE
Target $4
BTIG
Neutral
T2 Biosystems upgraded to Neutral from Sell at BTIG
BTIG analyst Karen Koski upgraded T2 Biosystems to Neutral saying shares have fallen below her prior $4 price target and believes the upcoming panel for T2Bacteria will act as a positive catalyst.
ZFGN Zafgen
$3.41

-0.08 (-2.29%)

04/20/17
ROTH
04/20/17
INITIATION
Target $9
ROTH
Buy
Zafgen initiated with a Buy at Roth Capital
Roth Capital analyst Sa'ar Yaniv started Zafgen with a Buy rating and $9 price target as he expects a number of events over the coming 12 months to drive investor interest.
01/06/17
01/06/17
UPGRADE
Target $8

Outperform
Zafgen upgraded to Outperform ahead of weight loss drug data at JMP Securities
As previously reported, JMP Securities analyst Jason Butler upgraded Zafgen to Outperform from Market Perform and set an $8 price target on the shares, as he believes the Phase 1 results for the company's second-generation MetAP2 inhibitor, ZGN-1061, will likely demonstrate proof-of-concept weight loss efficacy with a favorable safety profile.
QDEL Quidel
$32.24

-0.01 (-0.03%)

12/16/16
PIPR
12/16/16
DOWNGRADE
Target $22
PIPR
Neutral
Quidel downgraded to Neutral from Overweight at Piper Jaffray
Piper Jaffray analyst William Quirk downgraded Quidel to Neutral saying the current Street estimates largely include a stronger flu season. He sees limited upside from a "flu trade" and keeps a $22 price target for the shares.
02/17/17
KING
02/17/17
INITIATION
KING
Neutral
Quidel initiated with a Neutral at CL King
07/18/17
ADAM
07/18/17
UPGRADE
Target $42
ADAM
Buy
Quidel upgraded to Buy from Hold at Canaccord
Canaccord analyst Mark Massaro upgraded Quidel (QDEL) to Buy from Hold as it is a beneficial buyer of Alere (ALR) assets. The analyst said the deal doubles the company's revenues, is immediately accretive, was bought at a low multiple to market value, and provides the company with new platforms to add tests on. Massaro raised his price target to $42 from $25 on Quidel shares.
07/18/17
WBLR
07/18/17
UPGRADE
WBLR
Outperform
Quidel upgraded to Outperform from Market Perform at William Blair
William Blair analyst Brian Weinstein upgraded Quidel to Outperform following the company's acquisition of Alere's Triage assets. Canaccord Genuity this morning also upgraded the shares.
PI Impinj
$37.42

0.38 (1.03%)

06/27/17
06/27/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Impinj (PI) was downgraded to Sector Weight from Overweight by Pacific Crest analyst Brad Erickson based on valuation. 2. Mizuho analyst Haendel St. Juste downgraded Store Capital (STOR) to Neutral from Buy citing fair valuation following recent strength driven by Berkshire Hathaway's (BRK.A) investment. 3. Camtek (CAMT) was downgraded to Hold from Buy by Needham analyst Y. Edwin Mok, as he expects to see some deceleration as the PCB business normalizes and he believes large orders for back-end semi inspections are already reflected in the stock after its recent run-up. 4. Nomura Instinet analyst Dan Dolev downgraded Cintas (CTAS) to Neutral from Buy after lowering his FY18 uniform rental organic growth forecasts to 5% from 7%. 5. Atlantic Equities analyst Barry MacCarthy downgraded Hess Corp. (HES) and Schlumberger (SLB), both to Neutral from Overweight, given his view of the limited prospects for an oil price rebound. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/04/17
ADAM
08/04/17
NO CHANGE
Target $50
ADAM
Buy
Impinj price target lowered to $50 from $57 at Canaccord
Canaccord analyst T. Michael Walkley lowered his price target on Impinj to $50 from $57 following Q2 results and lowered guidance. The analyst noted delayed rollouts with a handful of customers in different verticals, including retail and healthcare, and said a single customer could represent several million endpoint IC's. Management maintained its long-term guidance and Walkley expects re-accelerating revenue growth in 2018 and beyond. As a results, Walkley maintained his Buy rating on Impinj shares.
06/27/17
PACS
06/27/17
DOWNGRADE
PACS
Sector Weight
Impinj downgraded on valuation at Pacific Crest
As noted earlier, Pacific Crest downgraded Impinj to Sector Weight from Overweight. Analyst Brad Erickson downgraded the stock based on valuation.
06/27/17
PACS
06/27/17
DOWNGRADE
PACS
Sector Weight
Impinj downgraded to Sector Weight from Overweight at Pacific Crest
MULE MuleSoft
$21.41

-0.12 (-0.56%)

04/11/17
WBLR
04/11/17
INITIATION
WBLR
Outperform
MuleSoft initiated with an Outperform at William Blair
William Blair analyst Bhavan Suri started MuleSoft with an Outperform rating.
06/08/17
OPCO
06/08/17
INITIATION
OPCO
Perform
MuleSoft initiated with a Perform at Oppenheimer
Oppenheimer analyst Ittai Kidron started MuleSoft with a Perform saying the current valuation tempers his enthusiasm for the name.
04/11/17
04/11/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. HSN, Inc. (HSNI) initiated with a Hold at Aegis. 2. BroadSoft (BSFT) initiated with a Neutral at Baird. 3. Canada Goose (GOOS) initiated with an Equal Weight at Morgan Stanley. 4. MuleSoft (MULE) was initiated with an Outperform at William Blair, an Overweight at Piper Jaffray, a Buy at Jefferies, an Equal Weight at Barclays, and a Neutral at JPMorgan, BofA/Merrill, and Goldman. 5. ProPetro Holding (PUMP) was initiated with an Outperform at Evercore ISI and Credit Suisse, an Overweight at Piper Jaffray, JPMorgan, and Barclays, a Strong Buy at Raymond James, and a Buy at Goldman. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
06/08/17
06/08/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. T-Mobile (TMUS) initiated with a Buy at Drexel Hamilton. 2. Mesoblast (MESO) initiated with an Overweight at Cantor. 3. Sherwin-Williams (SHW) reinstated with a Conviction Buy at Goldman Sachs. 4. MuleSoft (MULE) initiated with a Perform at Oppenheimer. 5. Knowles (KN) initiated with a Buy at Dougherty. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
SELB Selecta Biosciences
$17.89

-0.09 (-0.50%)

12/08/16
STFL
12/08/16
NO CHANGE
STFL
Selecta Biosciences price target raised to $32 from $23 at Stifel
Stifel analyst Thomas Shrader raised his price target on Selecta, saying that data on the company's SEL-212 treatment showed "initial proof of concept in humans with an acceptable safety profile for more serious disease states." He keeps a Buy rating on the shares.
MDXG MiMedx
$15.64

0.41 (2.69%)

05/12/17
CHLM
05/12/17
NO CHANGE
Target $19
CHLM
Buy
MiMedx price target raised to $19 from $15 at Craig-Hallum
Craig-Hallum analyst Matt Hewitt believes MiMedx's stock deserves a higher multiple given its history of strong revenue growth and increasing profitability and also thinks that many of the factors that have weighed on its share price have been addressed, proven unfounded or are now better understood by the investment community. Hewitt, who keeps a Buy rating on MiMedx, raised his price target on the shares to $19 from $15.
05/17/17
PIPR
05/17/17
NO CHANGE
Target $18
PIPR
Overweight
MiMedx price target raised to $18 from $15 at Piper Jaffray
Piper Jaffray analyst Matt O'Brien raised his price target for MiMedx Group shares to $18 after hosting investor meetings with management. Momentum in the company's core wound closure business continues and the franchise should generate "strong" revenue growth in the coming years, O'Brien tells investors in a research note. Further, the analyst expects pain management to a "meaningful value creator" for MiMedx over time. He keeps an Overweight rating on the shares.
05/23/17
FANA
05/23/17
DOWNGRADE
Target $11
FANA
Underweight
MiMedx downgraded to Underweight from Equal-Weight at First Analysis
First Analysis analyst Joseph Munda downgraded MiMedx Group to Underweight saying the valuation "appears strecthed" with the shares up 62% year-to-date. The analyst adds that he still lacks clarity on the impact of the company's ongoing litigation with former employees. He has an $11 price target for the stock.
06/26/17
NEED
06/26/17
NO CHANGE
Target $20
NEED
Strong Buy
MiMedx price target raised to $20 from $15 at Needham
Needham analyst Mike Matson raised his price target on MiMedx to $20 from $15 as he expects the upcoming top line data from the company's diabetic foot ulcer and venous leg ulcer to drive more doctors to use and more insurers to cover EpiFix. He keeps a Strong Buy rating on the stock.
SHOO Steven Madden
$42.50

0.1 (0.24%)

03/07/17
SBSH
03/07/17
NO CHANGE
SBSH
Steven Madden added to "Value Creators" SMID Focus List at Citi
Citi analyst Scott Chronert added Steven Madden (SHOO) to his firm's "Value Creators" SMID Focus List while removing Berry Plastics (BERY). Steven Madden is well positioning for current footwear fashion trends, Chronert tells investors in a research note.
02/27/17
02/27/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Steven Madden (SHOO) upgraded to Buy from Neutral at B. Riley by analyst Jeff Van Sinderen, who said last week's footwear show and latest channel checks underscore the company's potential for growth. 2. Illumina (ILMN) upgraded to Buy from Hold at Evercore ISI by analyst Ross Muken following customer checks that lead him to above consensus revenue forecasts. Muken believes Illumina will sell 750-1,300 NovaSeq boxes over the next several years as sequencing enters a new era of utility. 3. Carnival (CCL) upgraded Buy from Hold by Argus analyst John Staszak, who now believes that "continued " improvement in demand for cruises will improve the company's earnings and margins. 4. Cempra (CEMP) upgraded to Buy at Roth Capital by analyst Michael Higgins after the company announced positive Phase 3 results in the first of two skin infection studies with Taksta, and ahead of bone data in 2017. The analyst also raised his price target on the shares to $8 from $2.50. 5. Unilever (UN) upgraded to Neutral from Underperform at BofA Merrill Lynch by analyst David Hayes, citing valuation and his belief that the strategic review could accelerate margin development targets over the next 4 years. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/27/17
RILY
02/27/17
UPGRADE
Target $45
RILY
Buy
Steven Madden upgraded to Buy from Neutral at B. Riley
B. Riley analyst Jeff Van Sinderen upgraded Steven Madden to Buy and raised his price target for the shares to $45 from $40. Last week's footwear show and latest channel checks underscore the company's potential for growth, Van Sinderen tells investors in a research note.
02/24/17
ADAM
02/24/17
NO CHANGE
Target $45
ADAM
Buy
Steven Madden price target raised to $45 from $40 at Canaccord
Canaccord analyst Camilo Lyon raised his price target on Steven Madden to $45 from $40 following meetings with management. The analyst sees multiple trends spurring a strong spring season and sees the company as the only one in the firm's coverage that can continue to thrive in the challenged retail landscape because its supply model is geared to respond in near-real time to changing consumer tastes. Lyon reiterated his Buy rating on Steven Madden shares.
BNFT Benefitfocus
$29.05

1.075 (3.84%)

08/04/17
CHDN
08/04/17
DOWNGRADE
CHDN
Neutral
Benefitfocus downgraded to Neutral from Buy at Chardan
Chardan analyst Steven Wardell downgraded Benefitfocus to Neutral and cut its price target to $30 saying topline growth reacceleration has been pushed out to Q2 2018, or later, and shares lack near-term catalysts.
06/01/17
WBLR
06/01/17
UPGRADE
WBLR
Outperform
Benefitfocus upgraded to Outperform from Market Perform at William Blair
William Blair analyst Adam Klauber upgraded Benefitfocus to Outperform citing the company's "strong" selling season.
01/06/17
CHDN
01/06/17
INITIATION
Target $36
CHDN
Buy
Benefitfocus initiated with a Buy at Chardan
Chardan analyst Steven Wardell initiated Benefitfocus with a Buy and a $36 price target.
02/07/17
BREN
02/07/17
INITIATION
Target $36
BREN
Buy
Benefitfocus initiated with a Buy at Berenberg
Berenberg analyst Robert Lamb initiated Benefitfocus with a Buy and a $36 price target.
EW Edwards Lifesciences
$116.14

-0.02 (-0.02%)

07/27/17
JEFF
07/27/17
NO CHANGE
Target $132
JEFF
Buy
Edwards Lifesciences price target raised to $132 from $115 at Jefferies
Jefferies analyst Raj Denhoy raised his price target for Edwards Lifesciences to $132 saying the company last night posted another impressive TAVR quarter. The analyst keeps a Buy rating on the shares.
07/27/17
RHCO
07/27/17
NO CHANGE
RHCO
Edwards Lifesciences Q2 TAVR sales 'solid,' says SunTrust
SunTrust analyst Bruce Nudell believes that Edwards' Q2 TAVR sales were " very solid." The analyst notes that the company raised its guidance, and he keeps a Buy rating on the shares.
07/27/17
ADAM
07/27/17
NO CHANGE
Target $155
ADAM
Buy
Edwards Lifesciences mitral devices could drive revenue further, says Canaccord
Canaccord analyst Jason Mills noted the solid Q2 results for Edwards Lifesciences and cited its outstanding leverage to its TAVR revenue. The analyst believes a decade from now the company will possess a broad portfolio of transcatheter mitral devices that could drive revenue and operating leverage further. MIlls reiterated his Buy rating and raised his price target to $155 from $150 on Edwards Lifesciences shares.
07/27/17
BOFA
07/27/17
NO CHANGE
Target $150
BOFA
Buy
Edwards Lifesciences price target raised to $150 on strong Q2 at BofA/Merrill
BofA/Merrill analyst Bob Hopkins increased Buy rated Edwards Lifesciences' price target to $150 from $140 due to the strong Q2 report and increased 2017 guidance. The analyst sees upside to gross margin and earnings guidance given the robust pipeline and outlook and said the December analyst day should be a positive catalyst for shares.
FH FORM Holdings Corp
$1.13

-0.01 (-0.88%)

08/08/17
ROTH
08/08/17
INITIATION
Target $3
ROTH
Buy
FORM Holdings Corp initiated with a Buy at Roth Capital
Roth Capital analyst David Bain started FORM Holdings Corp with a Buy rating and a $3 price target as he believes the company is benefiting from an alltime high number of RFPs for airport spas, a growing, high-density airport terminal captive patron base, near-term margin enhancements, trends toward health and wellness spend, underpinned by millennials and near-term potential monetization of non-core assets, creating a pure-play health and wellness company, anchored by XpresSpa.
ITI Iteris
$6.40

-0.17 (-2.59%)

02/02/17
02/02/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Kite Pharma (KITE) and Juno Therapeutics (JUNO) were initiated with a Neutral at Wedbush. 2. Penske Automotive (PAG) was initiated with a Positive at Susquehanna, while Lithia Motors (LAD) and Group 1 Automotive (GPI) were initiated with a Neutral. 3. Nevsun Resources (NSU) initiated with a Market Perform at BMO Capital. 4. Corcept Therapeutics (CORT) initiated with a Buy at Ladenburg. 5. Iteris (ITI) initiated with a Buy at Craig-Hallum. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
02/02/17
CHLM
02/02/17
INITIATION
Target $9
CHLM
Buy
Iteris initiated with a Buy at Craig-Hallum
Craig-Hallum analyst Steven Dyer started Iteris with a Buy rating and $9 price target.
07/18/17
DOTC
07/18/17
INITIATION
Target $8
DOTC
Buy
Iteris initiated with a Buy at Dougherty
Dougherty analyst Jon FIsher initiated Iteris with a Buy and an $8 price target saying it is an accelerating growth story driven by emerging trends in Connected Vehicles, Autonomous Driving and Smart Cities and the need for transportation infrastructure to better integrate Mobile, Cloud, and API technologies with Data Analytics to leverage these opportunities.
NVRO Nevro
$85.50

-1.13 (-1.30%)

05/09/17
JMPS
05/09/17
NO CHANGE
JMPS
Nevro weakness overdone, says JMP Securities
After Nevro reported lower than expected Q1 revenue, JMP Securities analyst David Turkaly says that the results reflect the "growing pains of being a high-growth differentiated player in the MedTech space." The analyst continues to believe that the company's Senza product can take share in the U.S. and "further expand the market." The analyst thinks that the 15% decline in the stock after the market closed yesterday was overdone. He reiterates a $120 price target and Outperform rating on the shares.
07/05/17
JPMS
07/05/17
NO CHANGE
JPMS
Overweight
Nevro preannounced strong Q2 sales, says JPMorgan
JPMorgan analyst Michael Weinstein reiterates an Overweight rating Nevro shares saying the company this morning preannounced "strong" Q2 sales. He expects the stock to trade up on the U.S. performance and notes that his talks with management indicate the departure of Michael Enxing, VP of Sales, was in the works following the Q1 shortfall. The analyst recommends buying Nevro at current levels.
07/17/17
ADAM
07/17/17
NO CHANGE
ADAM
M&A in med-tech space will accelerate, says Canaccord
Canaccord analyst Jason Mills remains cautious in the med-tech space but believes M&A will continue to be a major theme. He noted the sector is trading at peak levels and recommends trading around core positions and looking for pullbacks to average down in favorite names. He said the most likely takeout names, in this order, are, Nevro (NVRO), AtriCure (ATRC), NxStage Medical (NXTM), iRhythm (IRTC), and Penumbra (PEN).
06/30/17
JPMS
06/30/17
NO CHANGE
Target $102
JPMS
Overweight
Nevro should be bought at current levels, says JPMorgan
JPMorgan analyst Michael Weinstein says he recommends buying Nevro shares at current levels following his firm's latest survey of the U.S. spinal cord stimulation market. The company's Senza has not lost its momentum, Weinstein tells investors in a research note, citing the survey's findings. While St. Jude gained some traction with the DRG launch and Burst, physician enthusiasm for Senza remains high and the expectation is for increased utilization, Weinstein adds. He reiterates an Overweight rating on Nevro and $102 price target and notes the stock is down 16% since the company's Q1 shortfall.
PEN Penumbra
$86.50

2.4 (2.85%)

05/10/17
BMOC
05/10/17
NO CHANGE
BMOC
Penumbra price target raised to $96 from $86 at BMO Capital
BMO Capital analyst Joanne K. Wuensch raised her price target on Penumbra after the company reported higher than expected revenue. She thinks that "the shift toward mechanical thrombectomy for stroke treatment remains a significant driver" for the stock, and she keeps an Outperform rating on the shares.
08/09/17
ADAM
08/09/17
NO CHANGE
Target $100
ADAM
Buy
Penumbra price target raised to $100 from $94 at Canaccord
Canaccord analyst Jason Mills raised his price target on Penumbra to $100 from $94 following Q2 results. The analyst noted an acceleration in its stroke business and expects the company to deliver robust growth for multiple years. Mills reiterated his Buy rating on Penumbra shares.
06/14/17
ADAM
06/14/17
NO CHANGE
Target $94
ADAM
Buy
Penumbra 3D recall likely an immaterial event, says Canaccord
Canaccord analyst Jason Mills noted Penumbra issued a voluntary field recall of four lots of its 3D stent retriever following a few issues of SR breaking and/or unraveling. The lots were built in the U.S. so this should not impact Canada or European sales and 3D sales are not material to the analyst's model in 2017. As a result, he believes the recall is immaterial and so reiterated Penumbra as a top pick. Mills also reiterated his Buy rating and $94 price target on Penumbra shares.
KITE Kite Pharma
$120.13

6.58 (5.79%)

07/13/17
MAXM
07/13/17
DOWNGRADE
MAXM
Hold
Kite Pharma downgraded to Hold from Buy at Maxim
07/10/17
JEFF
07/10/17
NO CHANGE
Target $121
JEFF
Buy
Jefferies ups Kite target to $121 on 'relatively benign' FDA docs
Jefferies analyst Biren Amin raised his price target for Kite Pharma (KITE) shares to $121 from $101 after the FDA posted briefing documents ahead of the July 12 committee meeting disusing Novartis' (NVS) CAR-T therapy CTL019. The documents for the first CAR-T therapy seem "relatively benign," Amin tells investors in a research note. The FDA's view of CAR-T therapies looks in-line with expectations, but the agency may require long-term follow-up of patients to assess for risk of secondary malignancies, Amin writes. He keeps a Buy rating on Kite Pharma. The stock in late morning trading is down 3% to $102.55.
07/13/17
SBSH
07/13/17
NO CHANGE
SBSH
Novartis vote bodes well for Kite and Juno, says at Citi
Citi analyst Robyn Karnauskas believes the FDA's unanimous vote in favor of Novartis' (NVS) CAR-T bodes well for Kite Pharma (KITE) and Juno Therapeutics (JUNO). Yesterday's panel meeting provides a preview of what Kite can expect ahead of its November 29 FDA action date, Karnauskas tells investors in a research note. She believes the expert commentary from the panel has "overarching implications" for Kite and Juno, both of which are developing CAR-T therapies for multiple indications.
07/13/17
07/13/17
DOWNGRADE

Hold
Kite Pharma downgraded to Hold at Maxim
As previously reported, Maxim analyst Jason McCarthy downgraded Kite Pharma to Hold from Buy as he believes approval and success in relapsed/refractory blood cancers is already being factored in at the stock's current valuation. While "there is much more to come" from T-cell based oncology therapies, the focus for Kite is set to shift to "not if, but when and how much," McCarthy tells investors.
ELGX Endologix
$4.31

0.15 (3.61%)

05/18/17
BTIG
05/18/17
DOWNGRADE
BTIG
Neutral
Endologix downgraded on new trial at BTIG
As noted earlier, BTIG downgraded Endologix to Neutral from Buy. Analyst Sean Lavin downgraded the stock after the company announced that following its meeting with the FDA it will not seek approval of its first generation Nelix device and will instead seek approval of its second generation Nelix device. Lavin notes that an additional clinical trial will have to be performed on the second generation device before it can be approved. He does not expect the device to reach the U.S. market until 2020. Target $7.
05/18/17
OPCO
05/18/17
DOWNGRADE
Target $5.5
OPCO
Perform
Endologix downgraded to Perform from Outperform at Oppenheimer
Oppenheimer analyst Steven Lichtman downgraded Endologix to Perform and lowered his price target for the shares to $5.50 from $10. The downgrade follows the company's announcement that it willseek U.S. approval of the Nellix EVAS System by conducting a confirmatory clinical study. BTIG and Stifel this morning also downgraded Endologix.
05/18/17
SPHN
05/18/17
DOWNGRADE
Target $6
SPHN
Equal Weight
Endologix downgraded to Equal Weight from Overweight at Stephens
Stephens analyst Chris Cooley downgraded Endologix to Equal Weight from Overweight after the company announced that its Nellix plans are delayed again and it will now seek U.S. approval of the Nellix EVAS System by conducting a confirmatory clinical study with its Gen2 device design. Cooley cut his price target on Endologix shares to $6 from $10.
05/18/17
05/18/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Symantec (SYMC) downgraded to Neutral from Buy at UBS with analyst Fatima Boolani citing a more balanced risk/reward. 2. Jack in the Box (JACK) downgraded to Sector Weight from Overweight at KeyBanc and to Market Perform from Outperform at Telsey Advisory. 3. Grainger (GWW) downgraded to Sell from Hold at Deutsche Bank with analyst John Inch saying the company is "positioned to quickly lose share" as competitors respond with price cuts of their own. 4. Stratasys (SSYS) downgraded to Hold from Buy at Jefferies with analyst James Kisner citing the recent rally in the shares and uncertainty around the timing of new manufacturing opportunities. The analyst raised his price target for the stock to $30 from $24 following the company's first quarter results. 5. Endologix (ELGX) was downgraded to Equal Weight from Overweight at Stephens, to Neutral from Buy at BTIG, and to Hold from Buy at Stifel. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
ZEN Zendesk
$25.81

-0.13 (-0.50%)

05/25/17
NORL
05/25/17
NO CHANGE
NORL
Twilio lower after Northland details relationship with Airbnb
Airbnb, which currently has 3M homes in 191 countries on its platform, currently utilizes Twilio (TWLO) for SMS and push notifications, Northland analyst Michael Latimore told investors earlier today in a research note. The analyst spoke with several customers and partners, including Airbnb and Zendesk (ZEN), at Twilio's user conference this week. For push notifications, Airbnb uses two vendors, and for SMS, the platform uses Twilio, Vonage's (VG) Nexmo, and a likely small regional player based out of China, Latimore writes. He notes that Airbnb has seen 400% volume growth over the past two years with similar forecasts for the future. Airbnb said 80% of its volume goes to Twilio, the analyst notes. Latimore adds, "Airbnb employees noted that they found the new products announced during the keynote to be intriguing, suggesting a potential for a further expanded relationship." Despite Latimore's belief that an expanded relationship is possible, investors seem to have concerns that Airbnb could diversify away from Twilio, with the shares down in early trading by 3%, or 86c, to $25.19. The analyst has an Outperform rating on the stock with a $30 price target.
07/24/17
PIPR
07/24/17
NO CHANGE
Target $33
PIPR
Overweight
Piper remains buyer of Zendesk after 'strong' Q2 checks
Piper Jaffray analyst Alex Zukin says his channel checks for Zendesk suggest a "solid" enterprise quarter with billings outperformance. The analyst notes his firm continues to be buyers of the stock at current levels. The company reports Q2 results on August 3. Zukin keeps an Overweight rating on Zendesk.
05/26/17
UBSW
05/26/17
NO CHANGE
Target $38
UBSW
Buy
Zendesk undervalued relative to peers, says UBS
UBS analyst Ian Strgar said Zendesk shares are currently trading below its peer group as investors grapple with a lack of confidence in its ability to reaccelerate growth in the second half of the year. The company's reacceleration is predicated on ramping its sales force and growing its pipeline of enterprise deals and Strgar views the uncertainty as a buying opportunity. Strgar reiterated his Buy rating and $38 price target on Zendesk shares.
05/05/17
PIPR
05/05/17
NO CHANGE
Target $33
PIPR
Overweight
Zendesk selloff a buying opportunity, says Piper Jaffray
Piper Jaffray analyst Alex Zukin recommends using the post-earnings weakness in shares of Zendesk as a buying opportunity. The analyst believes the outlook reflects some conservatism and feels the company "remains on track to outperform through the year." Zukin reiterates an Overweight rating on Zendesk with a $33 price target.
LCI Lannett
$17.28

0.675 (4.07%)

05/03/17
CHLM
05/03/17
NO CHANGE
Target $32
CHLM
Buy
Lannett price target lowered to $32 from $38 at Craig-Hallum
Craig-Hallum analyst Matt Hewitt lowered his price target for Lannett to $32 from $38 after the company noted that greater than anticipated price erosion in Q3 more than offset a meaningful year over year volume increase, culminating in a miss on revenues and adjusted EPS. The analyst reiterates a Buy rating on the shares, saying there are still several unique opportunities on the horizon for Lannett that give him reason for optimism.
02/02/17
CHLM
02/02/17
NO CHANGE
Target $38
CHLM
Buy
Lannett results should ease investor concerns, says Craig-Hallum
Craig-Hallum analyst Matt Hewitt says that despite ongoing fears regarding competitive pressures, Lannett continues to put up "solid results" while generating meaningful cash flows used to pay down Kremers Urban acquisition related debt. Further, the analyst believes that "strong execution" in Q2 along with news the company has subsequently paid down another $75M of the debt balance should go a long way to calm investor's concerns over leverage. He reiterates a Buy rating and $38 price target on the shares.
02/02/17
ROTH
02/02/17
NO CHANGE
Target $28
ROTH
Buy
Lannett price target lowered to $28 from $34 at Roth Capital
Roth Capital analyst Scott Henry lowered his price target for Lannett to $28 from $34 on valuation. The analyst says the company continues to produce "strong results" on the back of Levo revenues, but the risk profile is elevated given high product concentration and a high debt load. He reiterates a Buy rating on the shares.
05/01/17
BMOC
05/01/17
INITIATION
Target $29
BMOC
Market Perform
Lannett initiated with a Market Perform at BMO Capital
BMO Capital analyst Gary Nachman started Lannett with a Market Perform rating and $29 price target. Macro headwinds are "very challenging for many generic companies," the analyst tells investors in a research note.
UPLD Upland Software
$23.60

-0.25 (-1.05%)

07/14/17
ROTH
07/14/17
DOWNGRADE
Target $26
ROTH
Neutral
Upland Software downgraded to Neutral from Buy at Roth Capital
Roth Capital analyst Richard Baldry downgraded Upland Software to Neutral from Buy citing valuation as the stock approaches his $26 price target. While he expects Upland's core profitability to continue improving, he is somewhat concerned its acquisition prices may be rising, noting that it had to pay a higher multiple for its "complementary acquisition" of Waterfall International than most of its recent deals.
06/27/17
RHCO
06/27/17
INITIATION
RHCO
Buy
Upland Software initiated with a Buy at SunTrust
SunTrust analyst Tery Tillman started coverage of Upland Software with a $27 price target and a Buy rating. The analyst says that the company's acquisitions and growth "help quickly scale profitable recurring revenues and earnings accretion." He expects the company to make additional accretive acquisitions that will enable it to achieve leadership positions in a number of markets. He thinks that the stock's valuation is attractive.
05/12/17
ADAM
05/12/17
NO CHANGE
Target $25
ADAM
Buy
Upland Software should be bought aggressively on pullbacks, says Canaccord
Canaccord analyst Richard Davis believes the shares of Upland Software should continue to work higher so long as the company continues with its impressive margin trajectory. The analyst still finds the valuation reasonable and said he would be a more aggressive buyer on any kind of pullback. Davis reiterated his Buy rating and raised his price target to $25 from $23 on Upland Software shares.
04/25/17
ROTH
04/25/17
NO CHANGE
Target $22
ROTH
Buy
Upland Software price target raised to $22 from $18 at Roth Capital
Roth Capital analyst Richard Baldry raises his price target for Upland Software to $22 from $18 after the company announced another acquisition, namely RightAnswers for $17.2M in cash. The analyst believes the deal adds "knowledge management" capabilities to Upland Software's suite of tools and is expected to be immediately accretive to adjusted EBITDA. Baldry reiterates a Buy rating on the shares.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.